Orphalan and XO Life: Digital therapy support for patients with the rare hereditary disorder Wilson's disease

October 1, 2024

Munich, Germany, September 30, 2024 – Orphalan, an expert in the treatment of Wilson's disease, and XO Life, a leading digital health startup, have decided to collaborate in order to improve therapy and quality of life for patients with Wilson's disease. Alongside drug therapy for the hereditary disorder, patients can now use XO Life's ImpactMonitor™ platform. After registration, it provides access to validated medical content and personalized insights and enables documentation of the course of therapy. The digital support gives patients a tool for individual therapy support, which they can also use to map their therapy goals and progress for discussion with their doctor.

Wilson's disease: not curable, but usually treatable with good results

Wilson's disease, a rare hereditary disorder also known as copper storage disease, is currently not yet curable. However, with early diagnosis and correct and consistent therapy, for example with a chelating agent or zinc, the disease can usually be treated well.

Combined therapy: digital support for patients

Through the combined offering of digital therapy support with the ImpactMonitor™ platform, which supports daily medication, patients with the hereditary disorder Wilson's disease can access additional help that is available around the clock. They gain simplified access to validated medical content, can document their course of therapy, receive insights in comparison with anonymized data from other users, and actively manage their course of treatment.

In addition, the systematic recording of their own patient experiences, known as patient-reported experiences (PREs) or patient-reported outcomes (PROs), can be shared with the treating doctor. The aim is to further improve adherence, safety of use, and therapy success in patients with this chronic disease.

ImpactMonitor™ platform: a new standard in digital healthcare

Sybille Petersohn-Boschmann, Managing Director DACH at Orphalan, explains: “For us as a company, developing and providing innovative solutions for the needs of patients with rare diseases also means relying on the latest digital technologies. Within just three months, we implemented engaging, modern digital support for our patients with Wilson's disease using XO Life's ImpactMonitor™ platform.”

“The collaboration shows not only the possibilities XO Life offers with the ImpactMonitor™ platform, but also how they can be implemented easily and promptly. Together, we can thus make an important contribution to the future of healthcare,” says Dr. Friderike Bruchmann, Co-Founder & CEO of XO Life.

About Orphalan

Orphalan is an international company headquartered in Paris that develops and markets medicines for rare diseases. Founded in 2011, the company develops and distributes innovative therapies for people living with rare and debilitating diseases. The product has been approved for the treatment of Wilson's disease and is available in more than 20 countries.

For more information, visit: www.orphalan.com

About XO Life

With the ImpactMonitor™ platform, XO Life has created a globally unique meta-platform for digital product and therapy support for patients. During their product use or therapy, patients are supported with verified medical and health-related content, document their health and therapy progress, receive personalized insights and medical support from experts, and can exchange experiences with others.

Manufacturers can create their own product and therapy areas on the ImpactMonitor™ platform and offer them to their patients with their own branding, content, questions, and services. By providing personalized information and continuous support during treatment, manufacturers make an important contribution to treatment success, adherence, and safety of use.

XO Life works with global market leaders, SMEs, and rare disease companies in more than 30 indications. User engagement on the platform is 10 times higher than for an average digital health app, and more than 120,000 medical questions were answered in the last year alone. The ImpactMonitor™ platform is now available in all European countries and languages.

‍